A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.

NCT Number	NCT07683065
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
Enrollment	150 participants
Start Date	2026-07-15
Primary Completion	2027-01-15 (estimated)
Study Completion	2027-01-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-06